Get informed when a big investor buys or sells
+ FollowOvervalued by 153.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $19.34 Million |
|---|---|
| Enterprise Value | $29.34 Million |
| Earnings per Share | $-0.1 |
| Beta | -157.98 |
| Outstanding Shares | 45,038,244 |
| P/E Ratio | -4.4 |
|---|---|
| PEG | 10.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.43 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.14 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | -0.54 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tole...